Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A M Gray

Showing results (141-150 of 163) with videos related to

Pageof 17
Sort By:
European Journal of Pharmacology|March 6, 1995
Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioningM Rafieian-Kopaei, A M Gray, P S Spencer, et al.
British Journal of Cancer|September 3, 2009
An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United KingdomH E Campbell, M A Taylor, A L Harris, et al.
Peptides|January 1, 1997
Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscleF P O'Harte, A M Gray, Y H Abdel-Wahab, et al.
Diabetologia|June 25, 2013
UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82A J Hayes, J Leal, A M Gray, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 12, 2003
L-NAME (N omega-nitro-L-arginine methyl ester), a nitric-oxide synthase inhibitor, and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one], a cannabinoid agonist, interact to evoke synergistic hypothermiaS M Rawls, R J Tallarida, A M Gray, et al.
British Journal of Cancer|September 9, 2010
Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UKH E Campbell, A M Gray, A L Harris, et al.
BMJ Open|January 11, 2017
Cost-effectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let's Prevent Diabetes cluster-randomised controlled trialJ Leal, D Ahrabian, M J Davies, et al.
Diabetologia|April 19, 2005
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)P M Clarke, A M Gray, A Briggs, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 20, 2015
Impact of hip fracture on hospital care costs: a population-based studyJ Leal, A M Gray, D Prieto-Alhambra, et al.
British Journal of Urology|March 1, 1996
The Oxford Laser Prostate Trial: economic issues surrounding contact laser prostatectomyS R Keoghane, K C Lawrence, A M Gray, et al.
Pageof 17

Showing results (141-150 of 163) with videos related to

Sort By:
Pageof 17
European Journal of Pharmacology|March 6, 1995
Contrasting actions of acute or chronic paroxetine and fluvoxamine on morphine withdrawal-induced place conditioningM Rafieian-Kopaei, A M Gray, P S Spencer, et al.
British Journal of Cancer|September 3, 2009
An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United KingdomH E Campbell, M A Taylor, A L Harris, et al.
Peptides|January 1, 1997
Effects of non-glycated and glycated glucagon-like peptide-1(7-36) amide on glucose metabolism in isolated mouse abdominal muscleF P O'Harte, A M Gray, Y H Abdel-Wahab, et al.
Diabetologia|June 25, 2013
UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82A J Hayes, J Leal, A M Gray, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 12, 2003
L-NAME (N omega-nitro-L-arginine methyl ester), a nitric-oxide synthase inhibitor, and WIN 55212-2 [4,5-dihydro-2-methyl-4(4-morpholinylmethyl)-1-(1-naphthalenyl-carbonyl)-6H-pyrrolo[3,2,1ij]quinolin-6-one], a cannabinoid agonist, interact to evoke synergistic hypothermiaS M Rawls, R J Tallarida, A M Gray, et al.
British Journal of Cancer|September 9, 2010
Estimation and external validation of a new prognostic model for predicting recurrence-free survival for early breast cancer patients in the UKH E Campbell, A M Gray, A L Harris, et al.
BMJ Open|January 11, 2017
Cost-effectiveness of a pragmatic structured education intervention for the prevention of type 2 diabetes: economic evaluation of data from the Let's Prevent Diabetes cluster-randomised controlled trialJ Leal, D Ahrabian, M J Davies, et al.
Diabetologia|April 19, 2005
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72)P M Clarke, A M Gray, A Briggs, et al.
Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|August 20, 2015
Impact of hip fracture on hospital care costs: a population-based studyJ Leal, A M Gray, D Prieto-Alhambra, et al.
British Journal of Urology|March 1, 1996
The Oxford Laser Prostate Trial: economic issues surrounding contact laser prostatectomyS R Keoghane, K C Lawrence, A M Gray, et al.
Pageof 17